Compared with monotherapy, the combination therapy with ETO and siVEGF performed excellent and long-term inhibition of tumor proliferation and angiogenesis in orthotopic NSCLC with low biotoxicity. Here, RUNX1T1 is linked to non-small cell lung carcinoma.